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Abstract
HIV-infected patients appear to have a significantly greater risk of non-AIDS comorbidities
such as osteoporosis and atherosclerosis. Subjects with osteoporosis are at a higher risk of
developing cardiovascular disease than those with normal bone mass, therefore a possible
relation between these two conditions can be hypothesized. In the setting of HIV infection,
several factors might contribute to bone disease and endothelial dysfunction. The aim of
our study was to evaluate the relationship between bone and cardiovascular disease and to
investigate the role of traditional factors, T-cell phenotype and osteoprotegerin in HIV posi-
tive subjects on effective antiretroviral therapy. We included 94 HIV positive subjects on
antiretroviral therapy with virological suppression and 41 healthy subjects matched for age
and gender as a control group. Carotid-Intima Media Thickness (c-IMT) and bone mineral
density (BMD) were performed by ultrasound and DEXA, respectively. CD4+/CD8+ T-cell
activation, senescence and osteoprotegerin plasma levels were measured by flow-cytome-
try and ELISA, respectively. Among HIV positive patients, 56.4% had osteopenia/osteopo-
rosis and 45.7% had pathological c-IMT (>0.9mm). Subjects with pathological c-IMT and
BMD exhibited higher CD4+ and CD8+ activated, CD8+ senescent and osteoprotegerin than
subjects with normal c-IMT and BMD. HIV positive subjects with osteopenia/osteoporosis
had higher c-IMT than subjects with normal BMD, and linear regression analysis showed a
negative correlation between BMD and c-IMT. Several factors are implicated in the patho-
genesis of non-AIDS comorbidities in HIV positive patients. Osteoprotegerin together with
inflammation and immunosenescence in HIV positive patients could affect bone and vascu-
lar system and could be considered as a possible common link between these two
diseases.
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Introduction
With increasing life expectancy, HIV-infected patients appear to have a significantly greater
risk of non-AIDS comorbidities such as osteoporosis and atherosclerosis, important causes of
morbidity and mortality [1–3]. These two conditions have always been considered as unrelated
and their coexistence was attributed exclusively to age-related processes. Recently, a connection
between these two pathological conditions has been considered possible as they share genetic
and pathophysiological risk factors [4–6]. Recent studies have shown that subjects with osteo-
porosis are at higher risk of developing cardiovascular disease than those with normal bone
mass; furthermore, studies in animal models have shown that vascular calcification have mech-
anisms similar to those used in normal bone calcification [7]. In the setting of HIV infection,
chronic inflammation, immune activation, immunosenescence and the consequent increased
levels of pro-inflammatory cytokines might contribute to bone disease and endothelial activa-
tion/dysfunction [8–13]. The role of inflammation in the development of non-AIDS related
chronic complication has been extensively studied and several markers such as TNF-α, IL-1
and IL-6 have been shown to reliably indicate organ damage [14–17]. Furthermore, new solu-
ble markers including the RANK (Receptor activator of nuclear factor kappa-B)/RANKL
(Receptor activator of nuclear factor kappa-B ligand)/OPG (Osteoprotegerin) axis, a member
of the TNF superfamily, have emerged as a possible link between osteoporosis and cardiovascu-
lar disease. Mostly implicated in bone remodeling, the RANK/RANKL/OPG axis is involved in
immune and vascular system. In fact, RANKL, expressed by osteoblast cells and their precur-
sor, activates its receptor (RANK), expressed by osteoclast cells and their precursor, thus pro-
moting osteoclast formation, activation, and prolonging osteoclast survival. The effects of
RANKL are blocked by the secretory glycoprotein OPG, which acts as a decoy receptor for
RANKL [18–20]. Perturbations of the RANKL/OPG ratio are critical in the pathogenesis of
bone disease and have also been associated with changes in macrophages, dendritic cells and
lymphocytes, which are involved in systemic inflammation, osteoclastogenesis and atherogene-
sis [21–23].
The aim of our study was to evaluate the relationship between bone and cardiovascular dis-
ease and to investigate the role of traditional factors, T-cell phenotype and OPG in HIV posi-
tive subjects on effective antiretroviral therapy (ART).
Materials and Methods
Ethics statement
The study protocol designed according to the Helsinki Declaration II was approved by the eth-
ics committee of Azienda Policlinico Umberto I of Rome. All the patients gave written
informed consent to participate.
Patients
We recruited 94 HIV-infected subjects who had been on ART for 48 weeks with undetectable
viremia (<37 copies/ml) at the Department of Public Health and Infectious Diseases of
“Sapienza”University of Rome. As a control group, 41 HIV negative individuals matched for
age and gender were included. For each patient, we collected medical and family history, life-
style, smoking status, current and past ART, HIV-RNA zenith and nadir CD4+ cell count. Cur-
rent T lymphocytes CD4+ and CD8+ cell count was determined by flow cytometric analysis
(MACSQuant Analyser Miltenyi Biotec, Germany) and HIV-1 RNA plasma levels were
detected by a quantitative reverse polymerase chain reaction (Amplicor HIV monitor; Roche
Diagnostic System, Branchburg, NJ version1.5, l.o.d. 37 copies/ml). Calcium, vitamin D,
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triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density
lipoprotein cholesterol (LDL) were measured in blood samples. Systolic and diastolic Blood
Pressure (SBP and DBP) (mmHg), Body mass index (BMI) (kg/m2) and Framingham score
(%) were calculated and recorded for each individual. HIV positive subjects were stratified
according to the presence of two comorbidities (concomitant bone and endovascular damage,
Group A) or only one (bone or endovascular damage, Group B) or no comorbidity (Group C).
Inclusion criteria were: age>18 years old; HIV positive subjects on effective ART
(HIVRNA<37 cp/ml) since 48 weeks, HIV positive subjects with low cardiovascular disease
risk (Framinghamm risk score<10%,) and CMV positive serostatus.
Exclusion criteria were age<18 years, previous virological failure, Framingham score
>10%, CMV negative subjects, recent AIDS-defining illness, co-infection with hepatitis virus
and presence of other comorbidities (metabolic syndrome, diabetes mellitus, arterial hyperten-
sion, kidney disease and hormonal dysfunction).
Sample analyses
OPG levels were measured by ELISA kits (Biomedica Gruppe,Vienna, Austria). The detection
limit of assay was 0.12 pmol/l. Lymphocyte surface phenotypes were evaluated by flow cytome-
try using fresh peripheral blood. For the activation and the senescence analysis of T cells CD4+
and CD8+, the following fluorochrome-labeled antibodies were used: Pacific Blue-CD3 (BioLe-
gend, 500 uL), FITC-CD28 (BioLegend, 2 mL), PE-CD57 (BioLegend, 2 mL), PerCp/
Cy5.5-HLA DR (BioLegend, 500 uL), Pe/Cy7-CD8 (BioLegend, 2 mL), CD38-APC (BioLe-
gend, 2 mL), APC/Cy7-CD4 (BioLegend, 2 mL). The flow cytometer was calibrated using
MACSQuantTM Calibration Beads and for the automatic compensation marked beads
(BDTM CompBeads Anti -Mouse Ig, k) and unmarked beads (BDTM CompBeads Negative
Control, FBS) were used. For the lysis of red blood cells FACS Lysing Solution (BD, Lysing
Solution) was used. The flow cytometer used for the analysis was the MACSQuant Analyser
with 8 channels and the data were analyzed by using the FlowJo V10 Software. Before each
acquisition, both calibration and automatic compensation were performed. Immune activation
was defined as HLADR+ CD38+ whereas immunosenescence was defined as CD28-CD57+
[24–25].
Carotid intima media thickness measurement (c-IMT)
c-IMT measurement was obtained for each patient using a B-mode ultrasound recording with
a 7- to 14-MZ array probe (ESAOTE-technology). Patients had to lie in a supine position in a
dark room with a slight hyperextension and turning the neck to the opposite side. The com-
mon carotid, the bifurcation and at least the first 2 cm of the internal carotid were examined on
the long and short axes. In addition, 3 measurements were made at the far and near walls of
each internal carotid and specifically at the carotid bifurcation, the bulb and 1 cm after the
bifurcation. The mean value (expressed as mm) of the 3 measurements taken at each site of the
internal carotid (left and right) was calculated for each patient and used as the final measure-
ment of internal c-IMT. According to published population studies, we defined normal c-IMT
as IMT<0.9 mm and pathological c-IMT as IMT>0.9 mm. All the measurements of c-IMT
were performed by a single operator to avoid inter-operator differences [26].
Dual-energy X-ray absorptiometry (DEXA)
Bone densitometry using a DEXA device (Hologic QDR 2000 plus, Bedford, MA, USA) was
performed on all individuals. A technician obtained scans of the lumbar spine (L1–L4) and
proximal femur (neck and total hip) in the postero-anterior projection. The individuals for
Bone and Cardiovascular Diseases in HIV Positive Subjects
PLOS ONE | DOI:10.1371/journal.pone.0149601 February 25, 2016 3 / 13
whom it was impossible to assess at least three vertebral bodies were excluded from the analy-
sis. Individuals with fractured lumbar vertebrae and vertebrae exhibiting major degenerative
changes on radiography were excluded from the analysis to avoid artefacts in the measurement
of the BMD. To calculate the T and Z score at the lumbar spine and proximal femur, we used
the reference data supplied by the manufacturer. An experienced radiologist blinded to study
information read all DEXA scans. Results are expressed as BMD (g/cm2) obtained by dividing
the mineral content in the region of interest (ROI) by the area of the region. Each individual
was classified on the basis of T score as being either normal (T score>–1.0), osteopenic (T
score between –1.0 and –2.5) or osteoporotic (T score –2.5), following the World Health
Organization diagnostic criteria [27].
Statistical analysis
Continuous data were analyzed with Student's t test whereas the nonparametric Mann-Whit-
ney test was applied for values not normally distributed. Pearson’s correlation coefficient was
used for correlations. One-way ANOVA analysis was used to compare the three study groups.
A linear regression model was tested to evaluate the association between T-cell lymphocytes
phenotype, OPG, T-score and c-IMT. To explore the factors independently associated with
BMD, a multivariable logistic regression was performed. ROC (Receiver Operating Character-
istic) curve analysis was performed by PRISM version 5 for Windows (Grafpad software macK-
iev). Data were expressed as median (range) or mean±standard deviation (SD), as appropriate.
A p value of<0.05 was considered statistically significant. Statistical analyses were performed
using STATA (version 9) software (STATA Corp. LP, College Station, TX).
Results
Study population
Out of 94 HIV-infected subjects with a low risk of cardiovascular diseases (Framingham score
<10%), 72 (76.5%) were males and 22 (23.5%) females with a mean age of 47.4±11.4 years.
52.1% were not smokers and mean BMI was 20.7±2.4 kg/m2. Median nadir and current T lym-
phocytes CD4+ cells count was 195.5 cell/mmc (range 4–1318) and 643.5 cell/mmc (range
159–1705), respectively. Out of 94 HIV-infected subjects on ART, 62.7% were on protease
inhibitors and 37.3% on non-nucleoside reverse-transcriptase inhibitors based regimen. All the
patients were cytomegalovirus (CMV) positive. The mean plasma concentration of vitamin D
was 36.5±4.3 ng/dl, serum creatinine was 0.94±0.21 mg/dl, total cholesterol was 188.3±47.4
mg/dl, HDL cholesterol was equal to 48±14.6 mg/dl, LDL cholesterol was equal to 114±46.3
mg/dl and triglycerides were equal to 145.3±80.9 mg/dl. Mean SBP was 120.3±12.5 mmHg and
mean DBP was 80.2±10.6 mmHg. None of the subjects was receiving lipid-lowering therapy.
Clinical characteristics are summarized in Table 1.
Carotid-intima media thickness (c-IMT) and bone damage (DEXA)
assessment
Overall, 48/94 (51.1%) had two comorbidities, 16/94 (17%) had one comorbidity and 30/94
(31.9%) no comorbidity. c-IMT was higher in the HIV positive group than in the control
group (mean±SD: 0.85±0.17 vs 0.48±0.07 mm, p<0.0001). Among HIV positive patients, 52/
94 (55.3%) demonstrated a normal c-IMT whereas 42/94 (44.7%) had a pathological c-IMT.
The mean BMD value was 0,88±0.17 g/cm2, accordingly 42/94 (44.6%) had osteopenia/osteo-
porosis whereas 52/94 (55.4%) had normal BMD. 7/42 (16.6%) had osteoporosis and 35/42
(83.4%) osteopenia. Univariate analysis showed a positive correlation between c-IMT and age
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(p<0.001). A negative correlation between the c-IMT and nadir T cells CD4+ (p = 0.008)
emerged. Indeed, the HIV positive subjects with pathological c-IMT value had lower percent-
ages of nadir T lymphocytes CD4+ compared with those with normal c-IMT value (p = 0.032).
Moreover, univariate analysis showed a negative correlation between BMD and age (p<0.001),
nadir and current T cells CD4 (p = 0.034 and p = 0.008, respectively), OPG (p = 0.037). HIV
positive subjects with concomitant bone and endovascular damage (n = 48) had an increased
age (p<0.001) than the other two groups. HIV positive patients with osteopenia/osteoporosis
showed a higher c-IMT than patients with a normal BMD (M±SD: 0.910±0.171 mm vs 0.789
±0.157 mm; p<0.001) (Fig 1A). In univariate linear regression analysis, a negative correlation
between c.IMT and BMD (p<0.0001) was found (Fig 1B).
T cells phenotype and osteoprotegerin: correlation with bone and
endovascular damage
When compared to HIV-negative patients, HIV-positive subjects exhibited higher levels of T
lymphocytes CD4+ expressing HLA-DR+CD38+ (median values 1.6% vs 0.4%, p<0.0001) and
CD8+ HLA-DR+CD38+ (median values 2.1% vs 0.8%, p<0.0001). HIV-positive subjects exhib-
ited a higher level of T lymphocytes CD4+ and CD8+ CD28-CD57+ (median values 2.08% vs
Table 1. Clinical Characteristics.
HIV+ (n = 94) HIV- (n = 41) p-value
Age 47.4±11.4 45±10 p = 0.338
Sex 72 M, 22 F 30 M, 11 F p = 0.645
Smoke status (n, %)
no 49 (52.1%) 24 (58.5%) p = 0.621
yes 45 (47.9%) 17 (41.5%) p = 0.539
CD4+ (mmc) 685.8±395.5 705±234 p = 0.685
CD4+ % 27.3±7.6 34±8.3 p = 0.753
CD4+ (mmc) nadir 242.3±227.6 - n.a.
CD4+ % nadir 14.7±9.6 - n.a.
HIV-RNA zenith (cp/ml) 297218.1±114812.4 - n.a.
HIV-RNA (cp/ml) <37 <37 n.a.
ART (n, %) 94/94 (100%) - n.a.
PI based regimen 59/94 (62.7%)
NNRTI based regimen 35/94 (37.3%)
CMV serostatus (n, %) 94/94 (100%) 41/41 (100%) n.a.
Lipid-lowering therapy 0 (0%) 0 (%) n.a
SBP (mmHg) 120.3 ± 12.5 113.8 ± 19.4 p = 0.465
DBP (mmHg) 80.2 ± 10.6 79.5± 13.2 p = 0.285
Triglycerides (mg/dl) 145.3±80.9 110.3±39 p = 0.721
Total Colestherol (mg/dl) 188.3±47.4 134.3±48.4 p = 0.775
Colestherol HDL (mg/dl) 48±14.6 50.3±15.6 p = 0.386
Colestherol LDL (mg/dl) 114±46.3 113.2±26.2 p = 0.291
BMI (kg/m2) 21±2.2 20±1.9 p = 0.634
Framingham score (%) 7.1±2.8 4.2 ± 2.6 p = 0.454
Values are presented as mean (M) ± standard deviation (SD); ART: AntiRetroviral Therapy; PI: Protease Inhibitor; NNRTI: Non-nucleoside reverse-
transcriptase inhibitor; CMV: Cytomegalovirus; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HDL: High Density Lipoprotein; LDL: Low
Density Lipoprotein. BMI: Body Mass Index.
doi:10.1371/journal.pone.0149601.t001
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1%, p = 0.01, median values 7.44% vs 0.65%, p<0.0001, respectively) compared with HIV-neg-
ative patients. In univariate linear regression analysis, a positive correlation between CD8+
HLA-DR+CD38+ and CD8+ CD28-CD57+ (p = 0.002) was observed. In addition, there was an
inverse correlation between the nadir T cells CD4+and T cells CD4+ HLA-DR+CD38+
(p = 0.007). Despite not reaching statistical significance, a similar trend was observed for nadir
T cells CD4+ and immuneactivated CD8+ and immunosenescent, CD4+and CD8+ cells. There
was a positive linear regression between c-IMT and T lymphocytes CD8+ CD28-CD57+
(p<0.001) and an inverse correlation between BMD and T lymphocytes CD8+ CD28-CD57+
(p = 0.008).
The levels of immune activation of T cells CD4+ were found to be higher in HIV-positive
subjects with concomitant bone and endovascular damage compared to the other groups
(median CD4+ HLA-DR+CD38+: 2.2% Group A vs 0.79% Group B vs 1.23% Group C,
p = 0.004) whereas the same trend was found for T cells CD8+ HLA-DR+CD38+ without reach-
ing statistical significance (median CD8+ HLA-DR+CD38+: 2.2% Group A vs 1.78% Group B
vs 2.1% Group C, p = 0.087) (Fig 2A and 2B). Similarly, levels of immunosenescent lymphocyte
T CD8+ cells were found to be higher in HIV-positive subjects with concomitant bone and
endovascular damage compared to the other groups (median CD8+ CD28-CD57+: 10.3%
Group A vs 7.9% Group B vs 4.1 Group C%, p<0.001) whereas the same trend was found for T
cells CD4+ CD28-CD57+without reaching statistical significance (median CD4+ CD28-CD57+:
2.1% Group A vs 2% Group B vs 2% Group C, p = 0.867, (Fig 2C and 2D).
OPG plasma levels were significantly higher in HIV-infected patients than in healthy con-
trols (mean±SD: 6.59±4 pmol/l vs 3.5±1.2 pmol/l) (p<0.0001). In the univariate linear regres-
sion analysis, there was a positive correlation between plasma levels of OPG and CD8+
HLA-DR+CD38+ (p = 0.008). Moreover, the same trend was observed between OPG and T
cells CD4+ HLA-DR+CD38+, T cells CD4+ and CD8+ CD28-CD57+, although not statistically
significant. OPG plasma levels were found to be higher in HIV-positive subjects with concomi-
tant bone and endovascular damage compared to the other groups (mean±SD: 7.29±4.17
pmol/l Group A vs 7.74±5.9 pmol/l Group B vs 4.98±1.77 pmol/l Group A, p = 0.045) (Fig 3).
Multivariable logistic regression showed that only age (OR = 1.166; confidence interval [CI] =
Fig 1. c-IMT and BMD in HIV infected subjects. A. A higher c-IMT in HIV positive patients with a low BMD than in patients with a normal BMD was found.
Horizontal bars represent the median. The upper and lower whisker indicate the third quartile +1.5 [Inter Quartile Range (IQR)] and first quartile -1.5(IQR). B.
A linear regression analysis showed a negative correlation between c-IMT and BMD.
doi:10.1371/journal.pone.0149601.g001
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1.081–1.259; p<0.001) and T lymphocytes CD8+ CD28-CD57+ (OR = 1.097; CI = 1.014–1.186;
p = 0.021) were independently associated with the presence of two comorbidities (Table 2).
A ROC curve was performed to establish the cut-off point of T lymphocytes CD8+
CD28-CD57+ that correlated with the presence of two comorbidities. For a CD8+ CD28-CD57+
cut-off>8.87%, the area under the curve (AUC) was 0.79 with a sensitivity of 75,61% (CI:
59.7% to 87.64%), specificity of 78.85% (CI: 65.30% to 88.94%) and a likelihood ratio of 3.57
(p<0.0001) (Fig 4).
Discussion
Although antiretroviral therapy has changed the length and quality of life of HIV-positive
patients, morbidity and mortality due to non-AIDS-related complications, such as osteoporosis
and atherosclerosis, were increased, even in the presence of viral suppression [1]. Traditionally,
these two conditions have always been considered not related to each other and their coexis-
tence was exclusively an age-associated process [28]. However, recent studies have shown that
Fig 2. T cells phenotype in HIV infected subjects.CD4+ and CD8+ immune activation (A, B) and immunesenescence (C, D) in HIV-infected subjects
according to the presence of bone and vascular diseases: presence of two comorbidties (bone and endovascular damage), only one comorbidity (bone or
endovascular damage), no comorbidity. Values are expressed as a percentage. The horizontal bars represent the median. The upper and lower whisker
indicate the third quartile +1.5 [Inter Quartile Range (IQR)] and first quartile -1.5(IQR).
doi:10.1371/journal.pone.0149601.g002
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Fig 3. OPG plasma levels in HIV positive subjects.OPG plasma levels (pmol/l) in HIV-infected subjects according to the presence of bone and
endovascular damage: presence of two comorbidties (bone and endovascular damage), only one comorbidity (bone or endovascular damage), no
comorbidity. The horizontal bars represent median. The upper and lower whisker indicate the third quartile +1.5 [Inter Quartile Range (IQR)] and first quartile
-1.5(IQR).
doi:10.1371/journal.pone.0149601.g003
Table 2. Multivariate Analysis.
OR 95% IC p
Age 1.166 1.081–1.259 <0.001
Time of Diagnosis 1.034 0.958–1.116 0.392
Smoke Status 0.657 0.205–2.107 0.480
Nadir CD4+ 0.997 0.994–1.001 0.100
OPG 0.995 0.867–1.141 0.942
CD4+ HLA-DR+CD38+ 1.381 0.920–2.073 0.119
CD4+ CD28-CD57+ 1.038 0.896–1.203 0.620
CD8+ HLA-DR+CD38+ 0.890 0.733–1.080 0.238
CD8+ CD28-CD57+ 1.097 1.014–1.186 0.021
Multivariable logistic regression showed that only age and T lymphocytes CD8+ CD28-CD57+ were
independently associated with the presence of two comorbidities in HIV positive subjects. OR: Odd Ratio;
CI: Confidence Interval; OPG: Osteoprotegerin.
doi:10.1371/journal.pone.0149601.t002
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there is a possible link between the two pathological conditions by demonstrating that in the
general population, subjects with osteoporosis are at increased risk of developing cardiovascu-
lar disease compared to those with normal bone mass [5,29–30]. Although a recent study
showed that there was an increased in CD161-expressing and TNF secreting invariant Natural
killer T cells in HIV positive subject with concomitant bone and cardiovascular disease, sug-
gesting that these cells might have a role in the pathogenesis of non infectious co-morbidities
in HIV population, little is known on other cellular subsets involvement in HIV positive
patients [31].
Thus, in the present study, the relationship between bone and cardiovascular disease and T-
cell phenotype in HIV positive subjects on effective antiretroviral therapy (ART) was
evaluated.
Carotid-IMT values were found to be higher in HIV positive subjects than in healthy con-
trol and, more interestingly, HIV-positive patients with bone disease had higher values of c-
IMT than patients with a normal BMD, as shown by the inverse correlation between BMD and
c-IMT found at the univariate analysis. Besides the already known risk factors in the general
population (age, dyslipidemia, hypertension, smoking status, diabetes, hypovitaminosis D and
Fig 4. ROC curve analysis. The ROC curve area for CD8+CD28-CD57+ (AUC) was 0.79 and the cut-off >8.87% has a sensitivity of 75,61% (CI: 59.7% to
87.64%), specificity of 78.85% (CI: 65.30% to 88.94%) and a likelihood ratio of 3.57 (p<0.0001).
doi:10.1371/journal.pone.0149601.g004
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calcium deficiency), in HIV subjects there are additional and specific elements that might con-
tribute to the cumulative risk of developing cardiovascular and bone damage [32–34]. In fact
during HIV infection, a higher activation of T lymphocytes was observed, resulting in the pro-
duction of several inflammatory cytokines with subsequent state of chronic inflammation,
even in the case of an effective ART [35].
In the present study, HIV-positive subjects with concomitant bone and endovascular dam-
age showed a higher state of immune activation and immunosenescence of T cells CD4+ and
CD8+ plasma levels than subjects with one or no comorbidities.
It is known that HIV determines a state of chronic inflammation with activation and pro-
gressive aging of the immune system. An important aspect of this premature aging is the
immune activation and the consequent immunosenescence that causes a thymic involution, a
reduced circulating naive T-cells and an increased number of T cells CD28- [8].
In this study, the multivariable logistic regression showed that only age and T lymphocytes
CD8+ CD28-CD57+ were independently associated with the presence of two comorbidities; in
particular, the ROC curve revealed that a cut-off>8.87% of T lymphocytes CD8+ CD28-CD57+
correlated with the presence of concomitant bone and cardiovascular disease, suggesting that
the immune exhaustion during HIV infection might exert a prominent role in the development
of these conditions.
In the setting of the immune dysregulation present in HIV subjects, the role of traditional
pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α has been widely demonstrated [15].
Recently, the RANK/RANKL/OPG axis has emerged as a possible link between osteoporosis
and cardiovascular disease by playing a crucial role in the interaction between the immune sys-
tem and the development of cardiovascular and bone disease both in healthy and HIV positive
subjects [22–23, 36].
This hypothesis was confirmed by the results of the present study, in which a higher plasma
concentration of OPG in HIV positive subjects than healthy control and a positive correlation
with T lymphocytes CD8+ immune activated were found. Moreover, among HIV positive sub-
jects, OPG was higher in those who had concomitant bone and cardiovascular damage than in
those who had one or not comorbidity.
In fact, it has been shown in in-vitro studies that T lymphocytes influence the basal produc-
tion of OPG, especially in conditions of inflammatory states, where the activated T cells
become a significant additional RANKL source [37–38]. In these conditions, the high levels of
RANKL might be due to a greater synthesis of RANKL and/or to an insufficient increase of
OPG synthesis leading to an elevated RANKL/OPG ratio, which is associated with bone resorp-
tion and atherogenesis. On the other hand, in-vivo studies demonstrated that OPG plasma lev-
els were significantly higher in HIV-positive subjects than in healthy controls [36]. These data
suggest that HIV infection itself, together with ART, could act on T lymphocytes, osteoblasts
and stromal cells by increasing OPG synthesis and resulting in a compensatory mechanism to
counterbalance the expression of RANKL by these activated cells. The imbalance of the
RANKL/OPG ratio was associated with an alteration in the production of osteoblasts/osteo-
clasts at the onset of bone disease in HIV positive patients and in the development of cardio-
vascular disease, although there are still few and conflicting data about it. In particular, it seems
that OPG in-vitro protects vascular calcification whereas in-vivo higher OPG plasma levels are
significantly associated with endothelial dysfunction and the development of coronary heart
disease [36, 39–40]. In a previous study conducted by our group, high OPG plasma levels were
found in HIV patients with low cardiovascular risk but with organ damage, suggesting that
OPG plays a role in the early stages of the atherosclerotic process [41].
The mechanism throughout OPG might contribute to cardiovascular disease relies on endo-
thelial dysfunction by blocking RANKL, which is known to be able to activate protective
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pathways in endothelial cells such as nitric oxide synthase. In addition, OPG would increase
the adhesion and migration of inflammatory cells across the endothelium, the activity of metal-
loproteinases, the inhibition of apoptosis of inflammatory cells, smooth muscle cells and endo-
thelial cells with increased plaque instability [42–43].
The scenario of multiple comorbidities during HIV infection is complicated: virus, ART,
immune activation and immunosenescence with pro-inflammatory cytokines play a predomi-
nant role [44–45]. Several hypotheses have been advanced to explain the possible relationship
between bone and vascular disease as they recognize both risk factors and common pathophys-
iological mechanisms. Despite the fact that traditional factors should always considered in the
pathogenesis of non-AIDS related comorbidities in HIV-positive subjects, the perturbation of
the OPG/RANK/RANKL pathway, together with inflammation and immunesenescence, could
affect bone turnover and the vascular system, even in the case of viral suppression.
Conclusion
In the presence of a complex but still not fully understood interaction between HIV, immune
system and RANKL/OPG axis, OPG plasma levels together with the evaluation of immunose-
nescent CD8+ T cells might represent useful and non-invasive parameters in order to identify
early organ damage in asymptomatic HIV-positive subjects.
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